Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrel...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1496630/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850146443555241984 |
|---|---|
| author | Giang H. Ta Max K. Leong |
| author_facet | Giang H. Ta Max K. Leong |
| author_sort | Giang H. Ta |
| collection | DOAJ |
| description | The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrelvir was assessed using various in silico models. The prediction results suggest that Nirmatrelvir could be administrated via the transdermal route, offering a promising avenue to enhance the efficacy of anti-COVID-19 agents. |
| format | Article |
| id | doaj-art-4e4ed997753642f68241024f760cd8de |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-4e4ed997753642f68241024f760cd8de2025-08-20T02:27:50ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-11-011510.3389/fphar.2024.14966301496630Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insightGiang H. TaMax K. LeongThe clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrelvir was assessed using various in silico models. The prediction results suggest that Nirmatrelvir could be administrated via the transdermal route, offering a promising avenue to enhance the efficacy of anti-COVID-19 agents.https://www.frontiersin.org/articles/10.3389/fphar.2024.1496630/fullin silicoskin permeabilityPaxlovidnirmatrelvirCOVID-19 |
| spellingShingle | Giang H. Ta Max K. Leong Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight Frontiers in Pharmacology in silico skin permeability Paxlovid nirmatrelvir COVID-19 |
| title | Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight |
| title_full | Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight |
| title_fullStr | Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight |
| title_full_unstemmed | Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight |
| title_short | Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight |
| title_sort | mitigating paxlovid™ induced drug drug interaction toxicity an in silico insight |
| topic | in silico skin permeability Paxlovid nirmatrelvir COVID-19 |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1496630/full |
| work_keys_str_mv | AT gianghta mitigatingpaxlovidinduceddrugdruginteractiontoxicityaninsilicoinsight AT maxkleong mitigatingpaxlovidinduceddrugdruginteractiontoxicityaninsilicoinsight |